33,440% Sales Growth Over 3-Year Period Establishes AMDL, Inc. as Fastest-Growing Public Company in OC Area
October 22 2008 - 9:30AM
PR Newswire (US)
TUSTIN, Calif., Oct. 22 /PRNewswire-FirstCall/ --
(http://www.amdl.com/) AMDL, Inc. (AMEX:ADL), a vertically
integrated pharmaceutical company with major operations in China
and the US, today announced it has been named the #1 fastest
growing public company in the Orange County area by the Orange
County Business Journal (OCBJ). The OC Business Journal's list of
the 50 fastest-growing public companies is published as a part of
OCBJ's 2008 Annual Book of Lists which includes 60 other unique
listing categories. The list of the 50 fasted-growing public
companies is based on key metrics including the company's
three-year revenue and sales growth performance by percentage and
sales. Monday, the OCBJ unveiled its 2008 list and AMDL claimed the
coveted #1 position with revenue growth of over 33,400% and sales
exceeding $26 million between the period of June 30, 2005 and June
30, 2008. "This recognition is one we are very proud of," explained
Mr. Gary Dreher, AMDL's President and CEO. "The focus, dedication
and commitment we have to our shareholders have driven the
Company's overall performance well beyond our business and
financial forecasts and this award is a tangible representation of
our team's ability to successfully manage and execute to success.
I'm very proud of AMDL's progress and we will remain diligent in
our on-going efforts. This includes achieving $26 million in sales
in the second half of this year and $30 to $38 million in projected
revenues for fiscal year 2008." Specifically, Mr. Dreher credits
the Company's strong revenue growth primarily to its consistent
execution on key business initiatives, including the successful
acquisition of Jade Pharmaceuticals in 2006 and solid marketing,
sales, and expanded distribution of high profit products such as
its Goodnak(R) anti-aging product line, Domperidone anti-emetic
product and various off-label pharmaceuticals. Strong sales of
these products have driven AMDL's year-over-year revenue growth by
more than 100%, specifically in the past 24 months. The Company has
also hit key business milestones over the past 12 months that
position the AMDL for continued growth. This includes success in
obtaining regulatory approval by the United States Food and Drug
Administration (US FDA) for the AMDL ELISA DR-70(R) (FDP) cancer
test. To learn more about AMDL and its diverse portfolio of
diagnostic, cancer therapy and pharmaceutical and diagnostic
products visit http://www.amdl.com/ About AMDL: Headquartered in
Tustin, CA with operations in Shenzhen, Jiangxi, and Jilin, China,
AMDL, Inc., along with its subsidiary Jade Pharmaceutical Inc.
(JPI), is a vertically integrated bio-pharmaceutical company
devoted to the research, development, manufacturing, and marketing
of diagnostic, pharmaceutical, nutritional supplement, and cosmetic
products. The company employs approximately 320 people in the U.S.
and China. The Company has an additional 4 pharmaceutical and
diagnostic products under review by various regulatory authorities.
Forward Looking Statements: Safe Harbor Statement under the Private
Securities Litigation Reform Act of 1995: The statements contained
in this document include certain predictions and projections that
may be considered forward-looking statements under securities law.
These statements involve a number of important risks and
uncertainties that could cause actual results to differ materially
including, but not limited to, the performance of joint venture
partners, as well as other economic, competitive and technological
factors involving the Company's operations, markets, services,
products, and prices. With respect to AMDL Inc., except for the
historical information contained herein, the matters discussed in
this document are forward-looking statements involving risks and
uncertainties that could cause actual results to differ materially
from those in such forward-looking statements. Potential risks and
uncertainties related to the Company's access to additional
capital, competition and dependence on key management. AMDL
Contact: Kristine Szarkowitz Director-Investor Relations (Tel:)
206.310.5323 DATASOURCE: AMDL, Inc. CONTACT: Kristine Szarkowitz,
Director-Investor Relations of AMDL, +1-206-310-5323, Web site:
http://www.amdl.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jul 2023 to Jul 2024